NAGIOS: RODERIC FUNCIONANDO

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

dc.contributor.author	Piñana, Jose Luis
dc.contributor.author	Vazquez, Lourdes
dc.contributor.author	Calabuig, Marisa
dc.contributor.author	López-Corral, Lucia
dc.contributor.author	Martin Martin, Gabriel Andrés
dc.contributor.author	Villalon, Lucia
dc.contributor.author	Sanz-Linares, Gabriel
dc.contributor.author	Conesa-Garcia, Venancio
dc.contributor.author	Sanchez-Salinas, Andrés
dc.contributor.author	Gago, Beatriz
dc.contributor.author	Facal, Ana
dc.contributor.author	Risco Gálvez, Irene
dc.contributor.author	Olave, Maria T.
dc.contributor.author	Espigado, Ildefonso
dc.contributor.author	Lopez-Jimenez, Javier
dc.contributor.author	Hernández-Rivas, Jose Ángel
dc.contributor.author	Avendaño-Pita, Alejandro
dc.contributor.author	Arroyo, Ignacio
dc.contributor.author	Ferrer, Elena
dc.contributor.author	García-Cadenas, Irene
dc.contributor.author	González-Santillana, Clara
dc.contributor.author	Roldán-Pérez, Alicia
dc.contributor.author	Ferrer, Blanca
dc.contributor.author	Guerreiro, Manuel
dc.contributor.author	Suarez-Lledó, Maria
dc.contributor.author	Camara, Angela
dc.contributor.author	Campos-Beltrán, Diana
dc.contributor.author	Navarro, David
dc.contributor.author	Cedillo, Ángel
dc.contributor.author	Sureda, Anna
dc.contributor.author	Solano Vercet, Carlos
dc.contributor.author	Spanish Hematopoietic Stem Cell Transplantation Ce
dc.contributor.author	Martino, Rodrigo
dc.date.accessioned	2023-01-09T12:10:08Z
dc.date.available	2023-01-09T12:10:08Z
dc.date.issued	2023
dc.identifier.citation	Piñana, Jose Luis Vazquez, Lourdes Calabuig, Marisa López-Corral, Lucia Martin Martin, Gabriel Andrés Villalon, Lucia Sanz-Linares, Gabriel Conesa-Garcia, Venancio Sanchez-Salinas, Andrés Gago, Beatriz Facal, Ana Risco Gálvez, Irene Olave, Maria T. Espigado, Ildefonso Lopez-Jimenez, Javier Hernández-Rivas, Jose Ángel Avendaño-Pita, Alejandro Arroyo, Ignacio Ferrer, Elena García-Cadenas, Irene González-Santillana, Clara Roldán-Pérez, Alicia Ferrer, Blanca Guerreiro, Manuel Suarez-Lledó, Maria Camara, Angela Campos-Beltrán, Diana Navarro, David Cedillo, Ángel Sureda, Anna Solano Vercet, Carlos Spanish Hematopoietic Stem Cell Transplantation Ce Martino, Rodrigo 2023 One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients Blood Cancer Journal 13 1
dc.identifier.uri	https://hdl.handle.net/10550/84914
dc.description.abstract	The long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has been little explored. A prospective multicenter registry-based cohort study conducted from December 2020 to July 2022 by the Spanish Transplant and Cell Therapy group, was used to analyze the relationship of antibody response over time after full vaccination (at 3-6 weeks, 3, 6 and 12 months) (2 doses) and of booster doses with breakthrough SARS-CoV-2 infection in 1551 patients with hematological disorders. At a median follow-up of 388 days after complete immunization, 266 out of 1551 (17%) developed breakthrough SARS-CoV-2 infection at median of 86 days (range 7-391) after full vaccination. The cumulative incidence was 18% [95% confidence interval (C.I.), 16-20%]. Multivariate analysis identified higher incidence in chronic lymphocytic leukemia patients (29%) and with the use of corticosteroids (24.5%), whereas female sex (15.5%) and more than 1 year after last therapy (14%) were associated with a lower incidence (p < 0.05 for all comparisons). Median antibody titers at different time points were significantly lower in breakthrough cases than in non-cases. A serological titer cut-off of 250 BAU/mL was predictive of breakthrough infection and its severity. SARS-CoV-2 infection-related mortality was encouragingly low (1.9%) in our series. Our study describes the incidence of and risk factors for COVID-19 breakthrough infections during the initial vaccination and booster doses in the 2021 to mid-2022 period. The level of antibody titers at any time after 2-dose vaccination is strongly linked with protection against both breakthrough infection and severe disease, even with the Omicron SARS-CoV-2 variant.
dc.language.iso	eng
dc.relation.ispartof	Blood Cancer Journal, 2023, vol. 13, num. 1
dc.subject	Malalties transmissibles
dc.title	One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
dc.type	journal article	es_ES
dc.date.updated	2023-01-09T12:10:09Z
dc.identifier.doi	10.1038/s41408-022-00778-3
dc.identifier.idgrec	156239
dc.rights.accessRights	open access	es_ES